KR970704450A - 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri) - Google Patents

자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri) Download PDF

Info

Publication number
KR970704450A
KR970704450A KR1019970700509A KR19970700509A KR970704450A KR 970704450 A KR970704450 A KR 970704450A KR 1019970700509 A KR1019970700509 A KR 1019970700509A KR 19970700509 A KR19970700509 A KR 19970700509A KR 970704450 A KR970704450 A KR 970704450A
Authority
KR
South Korea
Prior art keywords
dosage unit
progesterone antagonist
gestagen
competitive progesterone
competitive
Prior art date
Application number
KR1019970700509A
Other languages
English (en)
Other versions
KR100365879B1 (ko
Inventor
클라우스 스퇴케만
크리스토프 흐발리즈
Original Assignee
클로제, 브뢰잠레
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클로제, 브뢰잠레, 쉐링 악티엔게젤샤프트 filed Critical 클로제, 브뢰잠레
Publication of KR970704450A publication Critical patent/KR970704450A/ko
Application granted granted Critical
Publication of KR100365879B1 publication Critical patent/KR100365879B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 약품을 제조하기 위해 연속적으로 경구 투여 되는 경쟁적 프로게스테론 길항제 개별 투약 단위 및 게스타겐 개별 투약 단위를 함께 포함하는 생성물 (경쟁적 프로게스테론 길항제는 각각의 개별 투약 단위에서 유산을 유도할 수 없는 정도의 양으로 존재함)의 용도에 관한 것이다.

Description

자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomata Uteri)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 연속적인, 경구 투여를 위해 경쟁적 프로게스테론 길항제 개별 투약 단위 및 게스타겐 개별 투약 단위를 함께 포함하는 생성물의 용도에 있어서, 경쟁적 프로게스테론 길항제를 포함하는 개별 투약 단위가 게스타겐을 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 약제의 제조를 위한 비유산-유도량만큼 포함하는 것을 특징으로 하는 생성물의 용도.
  2. 제1항에 있어서, 경쟁적 프로게스테론 길항제를 포함하는 개별 투약 단위가 일 1회 내지 주 1회의 투여를 위해 제공되는 생성물의 용도.
  3. 제2항에 있어서, 경쟁적 프로게스테론 길항제의 투약 단위가 일 1회의 투여를 위해 제공되는 생성물의 용도.
  4. 제2항에 있어서, 경쟁적 프로게스테론 길항제의 투약 단위가 주 1회의 투여를 위해 제공되는 생성물의 용도.
  5. 제1항에 있어서, 게스타겐의 투약 단위가 연속적인 날게 결쳐 매일 투여하기 위해 제공되는 생성물의 용도.
  6. 제5항에 있어서 2 내지 12의 게스타겐 투약 단위를 포함하는 생성물의 용도.
  7. 제6항에 있어서, 제공된 경쟁적 프로게스테론 길항제 1차 투약 단위 후 15일 또는 그 이후로부터 시작하여 게스타겐 투약 단위를 연속적으로 포함하는 생성물의 용도.
  8. 제6항에 있어서, 제공된 경쟁적 프로게스테론 길항제 1차 투약 단위 후 18일 또는 그 이후로부터 시작하여 게스타겐 투약 단위를 연속적으로 포함하는 생성물의 용도.
  9. 제6항에 있어서, 21일 또는 22일로부터 시작하여 게스타겐 투약 단위를 포함하는 생성물의 용도.
  10. 제1항 내지 9항중 어느 한 항에 있어서, 경쟁적 프로게프테론 길항제를 포함하는 투약 단위가 11β-((4-N,N-디메틸아미노)-페닐)-17β-히드록시-17α-프로피닐-4,9(10)-에스트라디엔-3-온 (RU-38486), 11β-((4-N,N-디메틸아미노)-페닐)-17β-히드록시-18-메틸-17α-프로피닐-4,9(10)-에스트라디엔-3-온, 11β-((4-N,N-디메틸아미노)-페닐)-17αβ-히드록시-17αβ-프로피닐-D-호모-4,9(10), 16-에스트라디엔-3-온, 11β-p-메톡시페닐-17β-히드록시-17α-에티닐-4.9(10)-에스트라디엔-3-온, 11β-(4-아세틸페닐)-17β-히드록시-17α-(프로프-1-이닐)-4.9(10)-에스트라디엔-3-온, EP-A-02 83 428로부터의 19,11β-다리 결합된 스테로이드, EP-A-0 404 283로부터의 10β-H 스테로이드, 11β-[(4-디메틸아미노)페닐]-17α-히드록시-17β-(3-히드록시프로필)-13α-메틸-4,9(10)-고나디엔-3-온 (오나프리스톤),11β-19-(4-아세틸페닐)-17β-히르록시-17α-(3-히드록시프로프-1(Z)-에닐)-4,9(10)-에스트라디엔-3-온,11β,19-(4-(시아노페닐)-17β-히드록시-17α-(3-히드록시프로프-1(Z)-에닐)-4-안드로스텐-3-온, 11β,19-(4-3-피리디닐)-0-페닐렌)-17β-히드록시-17α-(3-히드록시프로프-1(Z)-에닐)-4-안드로스텐-3-온,(6α-11β,17β)-11-(4-디메틸아미노페닐)-6-메틸-4',5'-디히드로스피로[에스트라-4.9-디엔-17.2'(3'H)-푸란]-3-온, (11β,17α)-11-(4-아세틸페닐)-17,23-에폭시-19,24-디노르콜라-4,9,20-트리엔-3-온, (7β,11β,17β)-11-(4-디메틸아미노페닐)-7-메틸-4',5'-디히드로스피로[에스트라-4,9-디엔-17,2'(3'H)-푸란]-3-온을 포함하는 군으로부터의 적어도 하나의 화합물을 포함하는 생성물의 용도.
  11. 제1항 내지 10항 중 어느 한 항에 있어서, 각각 경쟁적 프로게스테론 길항제를 포함하는 개별 투약 단위에 경쟁적 프로게스테론 길항제로서 11β-[(4-디메틸아미노)페닐]17α-히드록시-17β-(3-히드록시프로필)-13α-메틸-4,9(10)-고다니엔-3-온 (오나프리스톤) 0.01 내지 100㎎, 11β-((4-N,N-디메틸아미노)-페닐)-17β-히드록시-17α-프로피닐-4,9-(10)-에스트라디엔-3-온 (RU 486) 0.01 내지 100㎎,또는 생물학적 등량의 다른 경쟁적 프로게스테론 길항제가 포함되는 생성물의 용도.
  12. 제1항 내지 11항 중 어느 한 항에 있어서, 게스타겐을 포함하는 투약 단위가 게스토덴, 프로게스테론, 레보노르게스트렐, 시프로테론 아세테이트, 클로르마디논 아세테이트, 드로스피레논 (디히드로스피로레논), 노르에티스테론, 노르에티소테론 아세테이트, 노르게스티메이트, 데소게스트렐, 3-케토데스게스트렐 또는 다른 인공적인 또는 천연의 게스타겐을 포함하는 군으로부터의 적어도 하나의 화합물을 포함하는 생성물의 용도.
  13. 제1항 내지 12항 중 어느 한 항에 있어서, 각각 게스타겐을 포함하는 개별 투약 단위에 게스타겐으로 레보노르게스트렐 0.06 내지 6.0㎎, 시프로테론 아세테이트 0.2 내지 20㎎,게스토덴 0.03 내지 3.0㎎ 또는 데소게스트렐 0.02 내지 2.0㎎ 또는 작용 등량의 다른 게스타겐이 포함되는 생성물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700509A 1994-07-27 1995-07-27 프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제 KR100365879B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426601A DE4426601A1 (de) 1994-07-27 1994-07-27 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DEP4426601.4 1994-07-27

Publications (2)

Publication Number Publication Date
KR970704450A true KR970704450A (ko) 1997-09-06
KR100365879B1 KR100365879B1 (ko) 2003-03-10

Family

ID=6524269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700509A KR100365879B1 (ko) 1994-07-27 1995-07-27 프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제

Country Status (22)

Country Link
US (1) US6043234A (ko)
EP (1) EP0772441B1 (ko)
JP (1) JPH10502092A (ko)
KR (1) KR100365879B1 (ko)
CN (1) CN1124848C (ko)
AT (1) ATE213417T1 (ko)
AU (1) AU705618B2 (ko)
CA (1) CA2195425C (ko)
CZ (1) CZ292177B6 (ko)
DE (2) DE4426601A1 (ko)
DK (1) DK0772441T3 (ko)
ES (1) ES2172592T3 (ko)
FI (1) FI970260A (ko)
HU (1) HU226453B1 (ko)
IS (1) IS4407A (ko)
MX (1) MX9700309A (ko)
NO (1) NO970309L (ko)
NZ (1) NZ291417A (ko)
PL (1) PL318264A1 (ko)
PT (1) PT772441E (ko)
SK (1) SK10497A3 (ko)
WO (1) WO1996003130A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
EP1030669A2 (en) 1997-11-14 2000-08-30 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
US20080214512A1 (en) * 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
PL2148681T3 (pl) * 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP2983671B1 (en) 2013-04-11 2018-10-24 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868323A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
FR3078952B1 (fr) * 2018-03-16 2020-03-27 Arianegroup Sas Systeme de mise en orbite de travail pour un satellite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Also Published As

Publication number Publication date
DE4426601A1 (de) 1996-02-01
CZ20797A3 (en) 1997-05-14
CN1124848C (zh) 2003-10-22
DE59510069D1 (de) 2002-03-28
KR100365879B1 (ko) 2003-03-10
AU705618B2 (en) 1999-05-27
CZ292177B6 (cs) 2003-08-13
NO970309D0 (no) 1997-01-24
WO1996003130A1 (de) 1996-02-08
CA2195425C (en) 2008-03-11
AU3254395A (en) 1996-02-22
SK10497A3 (en) 1997-08-06
DK0772441T3 (da) 2002-05-27
ES2172592T3 (es) 2002-10-01
IS4407A (is) 1997-01-02
CA2195425A1 (en) 1996-02-08
JPH10502092A (ja) 1998-02-24
US6043234A (en) 2000-03-28
MX9700309A (es) 1997-05-31
CN1154067A (zh) 1997-07-09
PL318264A1 (en) 1997-05-26
ATE213417T1 (de) 2002-03-15
FI970260A0 (fi) 1997-01-22
NZ291417A (en) 1998-12-23
PT772441E (pt) 2002-08-30
EP0772441B1 (de) 2002-02-20
HU226453B1 (en) 2008-12-29
HUT77092A (hu) 1998-03-02
EP0772441A1 (de) 1997-05-14
FI970260A (fi) 1997-01-22
NO970309L (no) 1997-01-24

Similar Documents

Publication Publication Date Title
KR970704450A (ko) 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri)
RU2189819C2 (ru) Схемы приема прогестогена-антипрогестогена
KR960001371B1 (ko) 폐경기 전의 여성용 혼합 제형 및 이를 포함하는 팩
ES2218556T3 (es) Metodos de contracepcion.
US6225297B1 (en) Combination contraceptive
US20120028935A1 (en) Therapeutic Gestagens for the Treatment of Premenstrual Dysphoric Disorder
PT99782B (pt) Processo de fabrico de contraceptivos orais de baixo teor em estrogenio
JPH09502194A (ja) 少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤
JPH09503774A (ja) 閉経直前及び閉経後の女性に対するホルモン置換療法用の黄体ホルモン拮抗物質及び部分的アゴニスト作用を有する抗エストロゲンの組合わせ
RU96119957A (ru) Фармацевтический комбинированный препарат для гормональной контрацепции
AU2005235418C1 (en) Multi-phase contraceptive preparation based on a natural estrogen
AR016502A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.
US20090137537A1 (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
PT787002E (pt) Antagonistas de progesterona competitivos para controlo de fertilidade feminina orientado pela necessidade
JPH11511157A (ja) 避妊用複合調剤、複合調剤を含有するキット及び複合調剤の使用方法
US6642219B1 (en) Progestogen-antiprogestogen regimens
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
ZA200201621B (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT).
EP1178807B1 (en) Use of org 33245 in combined intermittent hormone therapy and contraception
RU97103327A (ru) Применение комбинированного продукта, содержащего конкурирующий антагонист прогестерона и гестаген, для изготовления лекарственного средства, предназначенного для лечения эндометриоза или leiomyomata uteri
AU3662300A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
MXPA01008772A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
AU5942700A (en) Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
MXPA98010747A (en) Regimes of progestogeno-anti-progestog

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071120

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee